MoonLake Immunotherapeutics (MLTX) - Net Assets
Based on the latest financial reports, MoonLake Immunotherapeutics (MLTX) has net assets worth $254.02 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($400.37 Million) and total liabilities ($146.35 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset allocation strategy of MoonLake Immunotherapeutics to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $254.02 Million |
| % of Total Assets | 63.45% |
| Annual Growth Rate | 22.04% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 304.62 |
MoonLake Immunotherapeutics - Net Assets Trend (2020–2025)
This chart illustrates how MoonLake Immunotherapeutics's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see MLTX stock market capitalisation.
Annual Net Assets for MoonLake Immunotherapeutics (2020–2025)
The table below shows the annual net assets of MoonLake Immunotherapeutics from 2020 to 2025. Also explore net asset growth rate of MoonLake Immunotherapeutics to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $304.48 Million | -32.84% |
| 2024-12-31 | $453.39 Million | -11.70% |
| 2023-12-31 | $513.49 Million | +646.71% |
| 2022-12-31 | $68.77 Million | +690.53% |
| 2021-12-31 | $-11.65 Million | -110.35% |
| 2020-12-31 | $112.48 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to MoonLake Immunotherapeutics's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 46039438400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.00K | 0.00% |
| Other Comprehensive Income | $604.00K | 0.20% |
| Other Components | $766.78 Million | 251.83% |
| Total Equity | $304.48 Million | 100.00% |
MoonLake Immunotherapeutics Competitors by Market Cap
The table below lists competitors of MoonLake Immunotherapeutics ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Supply Network Ltd
AU:SNL
|
$1.05 Billion |
|
Shandong Head Co Ltd
SHE:002810
|
$1.05 Billion |
|
eXp World Holdings Inc
NASDAQ:EXPI
|
$1.05 Billion |
|
STEVANATO GROUP SPA O.N.
F:87N
|
$1.05 Billion |
|
Dorian LPG Ltd
NYSE:LPG
|
$1.05 Billion |
|
Episil-Precision Inc
TW:3016
|
$1.05 Billion |
|
Blue Square Real Estate Ltd
TA:BLSR
|
$1.05 Billion |
|
I.E.S Holdings Ltd
TA:IES
|
$1.05 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MoonLake Immunotherapeutics's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 446,825,002 to 304,481,000, a change of -142,344,002 (-31.9%).
- Net loss of 227,318,000 reduced equity.
- New share issuances of 72,395,000 increased equity.
- Other comprehensive income decreased equity by 4,392,769.
- Other factors increased equity by 16,971,767.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-227.32 Million | -74.66% |
| Share Issuances | $72.39 Million | +23.78% |
| Other Comprehensive Income | $-4.39 Million | -1.44% |
| Other Changes | $16.97 Million | +5.57% |
| Total Change | $- | -31.86% |
Book Value vs Market Value Analysis
This analysis compares MoonLake Immunotherapeutics's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.61x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.63x to 2.61x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $7.60 | $12.35 | x |
| 2021-12-31 | $-0.32 | $12.35 | x |
| 2022-12-31 | $1.67 | $12.35 | x |
| 2023-12-31 | $10.09 | $12.35 | x |
| 2024-12-31 | $7.11 | $12.35 | x |
| 2025-12-31 | $4.72 | $12.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MoonLake Immunotherapeutics utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -74.66%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.39x
- Recent ROE (-74.66%) is below the historical average (-40.09%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -0.08% | 0.00% | 0.00x | 1.04x | $-11.34 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.38 Million |
| 2022 | -131.92% | 0.00% | 0.00x | 1.57x | $-69.40 Million |
| 2023 | -7.26% | 0.00% | 0.00x | 1.06x | $-85.57 Million |
| 2024 | -26.62% | 0.00% | 0.00x | 1.07x | $-163.62 Million |
| 2025 | -74.66% | 0.00% | 0.00x | 1.39x | $-257.77 Million |
Industry Comparison
This section compares MoonLake Immunotherapeutics's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | $254.02 Million | -0.08% | 0.58x | $1.05 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplan… Read more